What is the official website of Lilly Gastroenterology ?

The official website of Lilly Gastroenterology is https://e.lilly/4bSHvqm.

What is Lilly Gastroenterology's cybersecurity risk score?

Lilly Gastroenterology has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Lilly Gastroenterology experienced?

According to Rankiteo, Lilly Gastroenterology currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Lilly Gastroenterology been affected by any supply chain cyber incidents ?

According to Rankiteo, Lilly Gastroenterology has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Lilly Gastroenterology have SOC 2 Type 1 certification ?

According to Rankiteo, Lilly Gastroenterology is not certified under SOC 2 Type 1.

Does Lilly Gastroenterology have SOC 2 Type 2 certification ?

According to Rankiteo, Lilly Gastroenterology does not hold a SOC 2 Type 2 certification.

Does Lilly Gastroenterology comply with GDPR ?

According to Rankiteo, Lilly Gastroenterology is not listed as GDPR compliant.

Does Lilly Gastroenterology have PCI DSS certification ?

According to Rankiteo, Lilly Gastroenterology does not currently maintain PCI DSS compliance.

Does Lilly Gastroenterology comply with HIPAA ?

According to Rankiteo, Lilly Gastroenterology is not compliant with HIPAA regulations.

Does Lilly Gastroenterology have ISO 27001 certification ?

According to Rankiteo,Lilly Gastroenterology is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Lilly Gastroenterology operate in ?

Lilly Gastroenterology operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Lilly Gastroenterology have ?

Lilly Gastroenterology employs approximately None employees people worldwide.

Does Lilly Gastroenterology own any subsidiaries ?

Lilly Gastroenterology presently has no subsidiaries across any sectors.

How many LinkedIn followers does Lilly Gastroenterology have ?

Lilly Gastroenterology's official LinkedIn profile has approximately 1,751 followers.

What is the NAICS classification code for Lilly Gastroenterology ?

Lilly Gastroenterology is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Lilly Gastroenterology have a Crunchbase profile ?

No, Lilly Gastroenterology does not have a profile on Crunchbase.

Does Lilly Gastroenterology have a LinkedIn profile ?

Yes, Lilly Gastroenterology maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/lilly-gastroenterology-eu.

How many cybersecurity incidents has Lilly Gastroenterology experienced ?

As of October 20, 2026, Rankiteo reports that Lilly Gastroenterology has not experienced any cybersecurity incidents.

How many peer or competitor companies does Lilly Gastroenterology have ?

Lilly Gastroenterology has an estimated 5,778 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Lilly Gastroenterology

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Lilly Gastroenterology Vendor Cyber Rating & Cyber Score

e.lilly

Add Your Compliance Badge

Lilly unites caring with discovery to make life better for people around the world. When you engage with Lilly on LinkedIn (and any other of Lilly’s social media channels), you are agreeing to these Community Guidelines in addition to the Terms and Conditions or other legal notices provided by Lilly and those of LinkedIn.

Lilly Gastroenterology

Lilly Gastroenterology CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Lilly Gastroenterology Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Lilly Gastroenterology

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lilly Gastroenterology in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Lilly Gastroenterology in 2026.

Incident Types Lilly Gastroenterology vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lilly Gastroenterology in 2026.

Incident History - Lilly Gastroenterology (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Lilly Gastroenterology Subsidiaries

Lilly Gastroenterology

Pharmaceutical Manufacturing

Website: https://e.lilly/4bSHvqm

Company Size: 10,001+ employees

Eli Lilly and CompanyPharmaceutical Manufacturing

Eli Lilly ItaliaFabbricazione di prodotti farmaceutici

Lilly LatamFabricación de productos farmacéuticos

Lilly EspañaFabricación de productos farmacéuticos

Lilly IndiaPharmaceutical Manufacturing

Loading…

Lilly Gastroenterology Similar Companies

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Medical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Loading…

NEWS

Lilly Gastroenterology CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 15, 2025 08:00 AM

US FDA approves expanded use of Lilly's bowel disease drug

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-77684

SUMMARY

The Bluetooth Classic Hands-Free Profile HF role in subsys/bluetooth/host/classic/hfp_hf.c does not release the AT command buffers that are still queued on hf->tx_pending when the RFCOMM DLC goes down. hfp_hf_disconnected() only cancelled the work items and cleared hf->acl, and no other code path ever dequeues those buffers, so each one is permanently lost from the fixed hf_pool (CONFIG_BT_MAX_CONN + 1 buffers, i.e. two in the default configuration). The same function also left BT_HFP_HF_FLAG_CONNECTED set, and hfp_hf_create() wiped the object with memset() as soon as hf->acl was NULL, without checking whether hf->work, hf->slc_work or hf->deferred_work was still pending or running. The remote Audio Gateway peer controls the trigger end to end and needs no application involvement: an unsolicited +BCS: 1 response makes bcs_handle() call bt_hfp_hf_select_codec() and queue an AT+BCS buffer, which cannot be transmitted while BT_HFP_HF_FLAG_RX_ONGOING is set, and an immediately following RFCOMM DISC strands that buffer. Repeating the connect / +BCS / disconnect cycle a couple of times empties hf_pool for good. With the pool exhausted, HFP command sending fails permanently, and because hfp_hf_send_cmd() allocates with K_FOREVER (bt_rfcomm_create_pdu() → bt_conn_create_pdu()) from the Bluetooth RX context — where that timeout is not downgraded to K_NO_WAIT — one further +BCS from the peer parks the Bluetooth RX thread inside net_buf_alloc() with no possible waker, halting all HCI event processing until the device is rebooted. Separately, reusing the HF slot while a work handler was still queued or running allowed memset() to wipe live k_work items out from under the system workqueue, corrupting shared kernel workqueue state. Exploitation requires an established HFP session (for SSP devices L2CAP enforces authentication before the RFCOMM channel is reachable) and a build with CONFIG_BT_HFP_HF enabled.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 5.7)

cvss3

Base Score: 5.7

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.1

REFERENCES

CVE-2026-19595

SUMMARY

The user-mode syscall verifier z_vrfy_rtio_cqe_get_mempool_buffer() in subsys/rtio/rtio_syscalls.c validated its two output parameters, buff and buff_len, with K_SYSCALL_MEMORY_READ() rather than K_SYSCALL_MEMORY_WRITE(). Both are pure out-parameters: z_impl_rtio_cqe_get_mempool_buffer() stores the mempool buffer address and its length through them. The distinction is enforced by every architecture validator — arch_buffer_validate() on RISC-V PMP explicitly accepts the global __rom_region/__rodata_region for reads only, and the ARM MPU validators accept P_RO_U_RO and P_RW_U_RO regions for reads only — so a read-validated pointer is not necessarily writable by the calling thread. An unprivileged user-mode thread that has been granted access to an RTIO context (rtio_access_grant()) can invoke the rtio_cqe_get_mempool_buffer() syscall with buff/buff_len pointing at memory it may read but not write, and with a completion-queue entry whose flags field it fully controls (only RTIO_CQE_FLAG_MEMPOOL_BUFFER in flags[7:0] is required; flags[19:8] and flags[31:20] supply the block index and count). The kernel then performs a pointer-sized and a 4-byte store through those addresses while running in supervisor mode. Reaching the store requires CONFIG_USERSPACE together with CONFIG_RTIO_SYS_MEM_BLOCKS, the configuration behind RTIO_DEFINE_WITH_MEMPOOL; without the latter the implementation returns -ENOTSUP and writes nothing. Two outcomes follow. If the target lies in a memory-domain partition declared K_MEM_PARTITION_P_RW_U_RO (privileged read-write, user read-only), the kernel-mode store succeeds and deposits partly attacker-chosen values into memory the memory domain had marked read-only for that thread, bypassing the partition's write protection. If the target lies in globally readable but unwritable memory such as .text/.rodata in flash, the store faults in kernel mode; the fault is delivered to z_fatal_error() and the default k_sys_fatal_error_handler() halts or reboots the device, giving an unprivileged thread a reliable full denial of service. The read-permission check does bound the damage: the address must still be readable by the calling thread, so kernel-private memory cannot be targeted and no confidential data is disclosed. The fix replaces both checks with K_SYSCALL_MEMORY_WRITE(), so a thread lacking write permission is terminated by K_OOPS before the implementation runs; the cqe argument correctly remains read-validated.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:H

Impact Score

4.2

Exploitability

1.8

REFERENCES

CVE-2026-19178

SUMMARY

IBM Storage TS4500 Library 1.1.1.6 through 1.12.0.3 could allow a remote authenticated attacker to gain unauthorized administrative privileges due to a race condition.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:N

Impact Score

5.2

Exploitability

1.6

REFERENCES

https://www.ibm.com/support/pages/node/7292610

CVE-2026-112991

SUMMARY

The html_to_markdown expansion module in MISP Modules contains a server-side request forgery (SSRF) vulnerability in its is_safe_url() URL validation function. The BLOCKED_RANGES list used to reject unsafe destination addresses was incomplete, omitting several critical IP address ranges. Specifically, the following ranges were not blocked: 0.0.0.0/8 (unspecified, which routes to loopback on Linux), 100.64.0.0/10 (carrier-grade NAT per RFC 6598), ::/128 (IPv6 unspecified), fc00::/7 (IPv6 Unique Local Addresses), and fe80::/10 (IPv6 link-local). The existing list only covered IPv4 loopback (127.0.0.0/8), RFC 1918 private ranges, IPv4 link-local (169.254.0.0/16), and IPv6 loopback (::1/128). An authenticated user with the ability to create or modify MISP attributes that trigger the html_to_markdown expansion module could supply URLs pointing to these unblocked internal address ranges. Because the module fetches the URL server-side to convert HTML content to Markdown, the request is made from the MISP server's network context. This allows an attacker to probe and read responses from internal services, carrier-grade NAT infrastructure, or link-local endpoints that would otherwise be unreachable from external networks. IPv4-mapped IPv6 forms (e.g., [::ffff:0.0.0.0]) also bypassed the existing checks. The security impact is primarily confidentiality: an attacker can read data served by internal services reachable from the MISP server. The MISP instance itself is not compromised, but it is abused as a proxy to access otherwise restricted network resources.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: )

cvss4

Base Score: 6.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/misp/misp-modules/commit/98a1c2c2f297665dd8d4609e9cd644007a57516b

CVE-2026-112372

SUMMARY

A weakness has been identified in H3C Magic NX15 V100R017. This affects the function importprofile of the file /api/upload. This manipulation of the argument fileName causes path traversal. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. The vendor was contacted early about this disclosure.

Published

Date2026-10-19

Updated

Date2026-10-19

RISK INFORMATION (Score: 6.6)

cvss2

Base Score: 5.8

Complexity: LOW

AV:N/AC:L/Au:M/C:P/I:P/A:P

cvss3

Base Score: 6.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:L/VI:L/VA:L/SC:L/SI:L/SA:L/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.7

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Lilly Gastroenterology Vendor Cyber Rating & Cyber Score

Lilly Gastroenterology A.I CyberSecurity Scoring

Lilly Gastroenterology CyberSecurity News & History

Lilly Gastroenterology Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Lilly Gastroenterology

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Lilly Gastroenterology vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Lilly Gastroenterology (X = Date, Y = Severity)

Lilly Gastroenterology Subsidiaries

Lilly Gastroenterology

Lilly Gastroenterology Similar Companies

Sandoz

Grifols

PT Kalbe Farma, Tbk

Fresenius Kabi

Sanofi

Teva Pharmaceuticals

Viatris

Johnson & Johnson Innovative Medicine

Takeda

Lilly Gastroenterology CyberSecurity News

US FDA approves expanded use of Lilly's bowel disease drug

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Lilly Gastroenterology CyberSecurity News & History

Lilly Gastroenterology Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Lilly Gastroenterology

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Lilly Gastroenterology vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Lilly Gastroenterology (X = Date, Y = Severity)

Lilly Gastroenterology Subsidiaries

Lilly Gastroenterology

Lilly Gastroenterology Similar Companies

Sandoz

Grifols

PT Kalbe Farma, Tbk

Fresenius Kabi

Sanofi

Teva Pharmaceuticals

Viatris

Johnson & Johnson Innovative Medicine

Takeda

Lilly Gastroenterology CyberSecurity News

US FDA approves expanded use of Lilly's bowel disease drug

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo